Drugs · acquisition-cost intelligence
Uceris
budesonide· ingredient budesonideCorticosteroids· BUDESONIDE 9 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$11.99
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other budesonide products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| budesonide | $0.52084 | −$11.47 |
| Budesonide Inhalation Suspension | $0.69110 | −$11.30 |
| Budesonide Inhalation | $0.72986 | −$11.26 |
| Budesonide Inhalation Suspension | $0.76862 | −$11.22 |
| Budesonide | $1.39 | −$10.60 |
| budesonide | $9.31 | −$2.68 |
| BREYNA | $19.78 | +$7.79 |
Medicare Part D coverage · CY2026
On 272 plan formularies · typical tier 5
Prior auth 61% · Step therapy 3% · Quantity limit 63% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.